Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab

被引：0
|
作者：
Thorne, J. Carter [1 ]
Boire, Gilles [2 ]
Chow, Andrew [3 ]
Garces, Kirsten [4 ]
Liu, Fang [5 ]
Poulin-Costello, Melanie [4 ]
Walker, Valery [5 ]
Haraoui, Boulos [6 ]
机构：
[1] Southlake Reg Hlth Ctr, Newmarket, ON, Canada
[2] Univ Sherbrooke, Dept Med, Div Rheumatol, Sherbrooke, PQ J1K 2R1, Canada
[3] Credit Valley Rheumatol, Mississauga, ON, Canada
[4] Amgen Canada Inc, Mississauga, ON, Canada
[5] Optum, Burlington, ON, Canada
[6] Inst Rhumatol Montreal, Montreal, PQ, Canada
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
548
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-World Switching Patterns in Rheumatoid Arthritis Patients Receiving Abatacept, Adalimumab, Etanercept or Infliximab As Second-Line Biologic Therapy
    Meissner, Brian
    Rosenblatt, Lisa
    Trivedi, Digisha
    You, Min
    Hebden, Tony
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S857 - S857
  • [22] RETENTION RATES OF ADALIMUMAB, ETANERCEPT AND INFLIXIMAB AS FIRST AND SECOND-LINE BIOLOGIC THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY PRACTICE: THE MAINTAIN STUDY
    Frazier-Mironer, A.
    Cantagrel, A.
    Combe, B.
    Deschamps, V.
    Dougados, M.
    Flipo, R. -M.
    Logeart, I.
    Mariette, X.
    Schaeverbeke, T.
    Sibilia, J.
    Le Loet, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 221 - 222
  • [23] Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis
    Doan, Quan V.
    Chiou, Chiun-Fang
    Dubois, Robert W.
    JOURNAL OF MANAGED CARE PHARMACY, 2006, 12 (07): : 555 - 569
  • [24] Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
    Downey, Colum
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (06) : 536 - 550
  • [25] Comorbidity and Cost Burden of Patients Prior to Initiating Abatacept or Infliximab As First Line Biologic Therapy for the Treatment of Rheumatoid Arthritis
    Darkow, Theodore
    Trivedi, Digisha
    Meissner, Brian
    Rosenblatt, Lisa
    Hebden, Tony
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S485 - S486
  • [26] The drug survival of adalimumab compared to etanercept and infliximab in treatment of patients with rheumatoid arthritis in daily clinical practice
    Kievit, W.
    Fransen, J.
    Kupper, H. H.
    Van de Laar, M. A. F. J.
    De Rooij, D. J. R. A.
    De Gendt, C. M.
    Jansen, T. L.
    Ronday, K. H.
    Bruse, H. L. C.
    Moolenburgh, J. D.
    Janson, M.
    Van Oijen, P. C. M.
    Adang, E. M.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 325 - 325
  • [27] Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy
    Gómez-Puerta, JA
    Sanmartí, R
    Rodríguez-Cros, JR
    Cañete, JD
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (07) : 896 - 896
  • [28] BUDGET IMPACT OF ETANERCEPT VERSUS ADALIMUMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS IN BIOLOGIC -NAIVE PATIENTS IN THE UNITED KINGDOM
    Onishchenko, K.
    Tarallo, M.
    Curiale, C.
    Alexopoulos, S. T.
    VALUE IN HEALTH, 2018, 21 : S193 - S194
  • [29] THE EFFECT OF METHOTREXATE IN TREATMENT WITH ADALIMUMAB AND ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS
    l'Ami, M.
    Kneepkens, E.
    Krieckaert, C.
    Marsman, A.
    Ruwaard, J.
    Wolbink, G.
    Nurmohamed, M. T.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 708 - 709
  • [30] Meta-analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis
    Wiens, Astrid
    Venson, Rafael
    Correr, Cassyano J.
    Otuki, Michel Fleith
    Pontarolo, Roberto
    PHARMACOTHERAPY, 2010, 30 (04): : 339 - 353
12345